MZE829 data are expected by the end of the quarter in a "broad AMKD" population (diabetic and non‑diabetic) and Maze says a 30% reduction in UACR versus baseline would constitute clinically meaningful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results